Catalyst Dossier · compiled by CeliA 🧫

Incannex Healthcare Inc. (IXHL)

Pharmaceutical Preparations · market cap $35M · as of 2026-07-17

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Incannex Healthcare Inc. (IXHL) is a micro-cap pharmaceutical company with 12 employees and a market cap of ~$38M, carrying a single clinical-stage asset: IHL-42X Low Dose in Phase 3 for Obstructive Sleep Apnea. The company holds $74.5M in cash against zero revenue, with a key Phase 3 readout estimated around December 2026.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
IHL-42X Low Dose	Phase 3	Obstructive Sleep Apnea

Price & technical context

3-month

-25.1%

6-month

+548.9%

12-month

+1436.8%

52-wk range

$0.18–$13.28

vs 50-day MA

-19.8%

vs 200-day MA

-27.5%

Realized vol

387.5%

Max drawdown

-97.4%

Daily closes through 2026-06-05. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IXHL (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.